RSS Feed For (NASDAQ:AUXL)

AUXILIUM PHARMACEUT (NASDAQ:AUXL)

34.93 0.07 (0.2%)
AUXILIUM PHARMACEUT (NASDAQ:AUXL) Delayed :
Previous Close $35.00    52 Week High $37.28 
Open $35.01    52 Week Low $17.96 
Day High $35.22    P/E N/A 
Day Low $34.68    EPS $-1.27 
Volume 332,156       
More AUXL Info: Chart SEC Filings Profile Historical Options

What is this?Friends, Peers and Foes

Ticker # Stories Ticker # Stories
PFE 4 CPY 2
XL 2 GSK 2
TTWO 2 ARYX 2
CPHD 2 CCE 2
GM 1 TRA 1
BMRN 1 DINE 1
View All Friends, Peers and Foes

StreetInsider Reports on AUXL by Category

Comments on recent AUXL articles

linda butti
on Sep 9, 2009
at 09:41 PM
XIAFLEX(TM)for duentren's I am interested in information on this new treatment
Article: Auxilium Pharmaceuticals (AUXL) XIAFLEX for the Treatment of Dupuytren's Contracture Receives Priority Review From the FDA
paul
on Jun 23, 2009
at 07:24 PM
xiaflex THE OFF LABEL INDICATIONS FOR A COLLAGENASE BASED INJECTIBLE FOR BURN SCARS, POST SURGICAL SCARS, KELOIDS, AS WELL AS OTHER INDICATIONS WOULD GREATLY EXPAND THE USE OF XIAFLEX.
Article: Hapoalim Securities Initiates Coverage on BioSpecifics (BSTC) with a Market Outperform; Possible Acquisition Play
Bob
on Jun 11, 2009
at 03:53 PM
Breen I am interested in knowing when you think this drug will be available to patients. Thanks
Article: Auxilium Pharmaceuticals (AUXL) XIAFLEX for the Treatment of Dupuytren's Contracture Receives Priority Review From the FDA
Paul
on Jul 25, 2008
at 12:16 PM
Xialfex The Citi analyst is missing the boat entirely. Not only is the market for Duputyren's larger than thought... based upon many patients going to doctors and are told there is nothing a doctor can do other than surgery, thereby patients never coming back to the physician...but.. and it is a big but...there are many other applications for XIAFLEX that are not now being evaluated yet offer tremendous potential for use. For example, as an "off label" indication. If approved for Dupuytren's does anyone not believe that patients would not seek out a urologist to use the XIAFLEX to treat Peyronie's prior to gaining FDA approval if it means being able to obtain a healthy and normal erection and have satisfactory sex.. How much would any man pay for being able to enjoy a "normal" sex life? Nowhere is it mentioned of the potential of XIAFLEX to be used in the burn marketplace to treat horrific scarring. Nowhere is it mentioned that XIAFLEX has the potential to treat keloids in patients with hyperpigmented skin. How many patients would beg and borrow money to be able to reduce a facial scar that can be so disfiguring, or to treat earlobes that are enlarged to the size of grapes due to an ear piercing procedure that "went bad?" There are other potential indications as well. The analyst is so wrong he/she should reexamine his/her positon after going out into the marketplaces and determing the true potential for this possibly explosive drug intervention. It is sad that folks right artilces/editorials that persude/dissaude folks from purchasing stock, and yet the so-called experts are really not experts at all.u
Article: Citi Downgrades Auxilium Pharmaceuticals (AUXL) to Hold

Comments on AUXL


No comments are currently available.